1. Histone modifications in epigenetic regulation of cancer: Perspectives and achieved progress
- Author
-
Yulia R. Aleksandrova, Sergey G. Klochkov, Gjumrakch Aliev, and Margarita E. Neganova
- Subjects
0301 basic medicine ,Cancer Research ,Cancer ,Antineoplastic Agents ,Computational biology ,Histone acetyltransferase ,DNA Methylation ,Biology ,medicine.disease ,Epigenesis, Genetic ,Chromatin ,Histone Code ,03 medical and health sciences ,030104 developmental biology ,0302 clinical medicine ,Histone ,Acetylation ,Neoplasms ,030220 oncology & carcinogenesis ,Histone methyltransferase ,medicine ,biology.protein ,Humans ,Epigenetics ,Histone deacetylase - Abstract
Epigenetic changes associated with histone modifications play an important role in the emergence and maintenance of the phenotype of various cancer types. In contrast to direct mutations in the main DNA sequence, these changes are reversible, which makes the development of inhibitors of enzymes of post-translational histone modifications one of the most promising strategies for the creation of anticancer drugs. To date, a wide variety of histone modifications have been found that play an important role in the regulation of chromatin state, gene expression, and other nuclear events. This review examines the main features of the most common and studied epigenetic histone modifications with a proven role in the pathogenesis of a wide range of malignant neoplasms: acetylation / deacetylation and methylation / demethylation of histone proteins, as well as the role of enzymes of the HAT / HDAC and HMT / HDMT families in the development of oncological pathologies. The data on the relationship between histone modifications and certain types of cancer are presented and discussed. Special attention is devoted to the consideration of various strategies for the development of epigenetic inhibitors. The main directions of the development of inhibitors of histone modifications are analyzed and effective strategies for their creation are identified and discussed. The most promising strategy is the use of multitarget drugs, which will affect multiple molecular targets of cancer. A critical analysis of the current status of approved epigenetic anticancer drugs has also been performed.
- Published
- 2022
- Full Text
- View/download PDF